Whitepapers

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Resource Types

How to overcome solubility challenges by applying amorphous solid dispersion: An end-to-end solution
Introduction Poor solubility is among the primary causes of low bioavailability for orally administered drugs. Because over 85% of pharmaceuticals are administered orally, improving solubility...
Read
Read
Harnessing artificial intelligence and digital technologies across the biopharma value chain
Introduction Artificial intelligence (AI) has the potential to revolutionize drug development through improved efficiency, accuracy, and speed. However, research indicates that biopharma companies have been...
Read
Read
Antibody Drug Conjugates Re-emergence of an old modality for targeted therapies
Introduction Antibody drug conjugates (ADCs) are a class of targeted drugs composed of a cytotoxic payload linked to an antibody that targets a cancer cell, designed...
Read
Read
Quality management paradigm shift: Risk-centric practices take center stage
Introduction The pharmaceutical industry is witnessing a paradigm shift in quality management (QM) as risk-based approaches become integral to ensuring compliance and efficiency. With the...
Read
Read
Protein therapeutics to amp-up outsourcing in animal health
Introduction The animal health industry is experiencing rapid growth, driven by increasing pet ownership and rising demand for advanced veterinary treatments. Protein therapeutics, particularly monoclonal...
Read
Read
CROs at the High Table of Drug Discovery
Introduction Contract Research Organizations (CROs) have evolved from simple service providers to key strategic partners in drug discovery. Initially, pharmaceutical companies outsourced limited tasks to...
Read
Read
Inside the growing precision therapy market and the crucial role of pDNA manufacturing
Introduction The precision therapy market is rapidly expanding, driven by breakthroughs in mRNA-based treatments, viral vector-based gene therapies, and gene-modified cell therapies. A crucial component...
Read
Read
Antibody Drug Conjugates: Re-emergence of an old modality for targeted therapies
Introduction Antibody drug conjugates (ADCs) are a class of targeted drugs composed of a cytotoxic payload linked to an antibody that targets a cancer cell, designed...
Read
Read